Salute e Benessere
BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Closing of Debt Settlement Transaction
The issuance of the revocation order on March 20, 2025 , follows the filing by the Company of its audited annual financial statements for the year ended October 31, 2024 , the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO Certifications of Annual Filings (collectively, the " ") on March 19, 2025 .
In addition to completing the Required Filings, the Company confirms it has also filed its interim financial statements for the three months ended January 31, 2025 , its management's discussion and analysis for the three months ended January 31, 2025 , and related filings, which were also required to be filed under National Instrument 51-102 . All of the Company's filing are available under the Company's profile on SEDAR+ at www.sedarplus.ca.
The Company also announces that, further to its news release dated April 1, 2025 , it has issued 1,200,000 common shares in the capital of the Company (each, a " ") at a deemed value of $0.05 per Share in settlement of an aggregate of $60,000 in debt owed to a lender of the Company (the " ").
All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation.
This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
BioVaxys common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
Signed " "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
Logo - https://mma.prnewswire.com/media/2415135/5262883/BioVaxys_Technology_Corp_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-announces-revocation-of-management-cease-trade-order-and-closing-of-debt-settlement-transaction-302426142.html